Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Offer Update

4 Aug 2005 09:43

Torex Retail PLC04 August 2005 Torex Retail plc4 August 2005 FOR IMMEDIATE RELEASE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN TOREX RETAIL PLC ___________________________________________________________________________ RECOMMENDED OFFER FOR XN CHECKOUT HOLDINGS PLC Offer Wholly Unconditional and Compulsory Acquisition of Outstanding XN Checkout Shares The Board of Torex Retail plc ("Torex Retail") announces that the offer (the"Offer") made by Evolution Securities Limited on behalf of Torex Retail for XNCheckout Holdings PLC ("XN Checkout") has today become wholly unconditional. As at 1.00 p.m. on 3 August 2005, valid acceptances had been received in respectof 26,884,727 XN Checkout Shares (representing approximately 96.03 per cent. ofXN Checkout's issued share capital). Accordingly, Torex Retail will shortly be issuing notices under s.429 CompaniesAct 1985 to XN Checkout Shareholders who have not yet accepted the Offer that itnow intends to exercise its rights to acquire compulsorily all those XN CheckoutShares still outstanding at the expiry of the requisite notice period. In themeantime, the Offer remains open for acceptance until further notice. Notice will also be sent to the Board of XN Checkout requesting that the XNCheckout Directors make an application to AiM for cancellation of the admissionof XN Checkout Shares to trading on AiM. XN Checkout Shareholders who have not yet accepted the Offer should, if theyhold their XN Checkout Shares in Certificated Form, despatch their Forms ofAcceptance as soon as possible or, if they hold their XN Checkout Shares inUncertificated Form accept the Offer electronically through CREST. XN CheckoutShareholders who are in any doubt as to the procedures for acceptance shouldcontact Capita Registrars by telephone on 0870 162 3121 or if calling fromoutside the United Kingdom on +44 208 639 2157. Settlement of consideration to which any XN Checkout Shareholder is entitledwill be effected: (i) in the case of acceptances received (complete in allrespects) by 4 August 2005 within 14 days of this date; or (ii) in the case ofacceptances received (complete in all respects) after 4 August 2005 but whilethe Offer remains open, within 14 days of such receipt. Terms defined in the Offer document dated 8 July 2005 shall, unless the contextrequires otherwise, have the same meanings in this announcement. EnquiriesTorex Retail Telephone: 01993 230 030Richard Thompson / Nigel Horn Evolution Telephone: 0207 071 4300Tim Worlledge / Jeremy Ellis This announcement is issued by Evolution which is authorised and regulated inthe United Kingdom by the Financial Services Authority. Evolution is actingexclusively for Torex Retail and is acting for no one else in connection withthe Offer and will not be responsible to anyone other than Torex Retail forproviding the protections afforded to customers of Evolution nor for providingadvice in relation to the Offer. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
24th May 201812:12 pmRNSResult of AGM
2nd May 20187:00 amRNSTRX BioSurgery GPO agreement with Premier, Inc.
27th Apr 20187:00 amRNSPosting of Annual Report and Notice of AGM
24th Apr 20187:00 amRNSDermaPure manufacturing at CellRight Facility
19th Apr 20183:29 pmRNSHolding(s) in Company
5th Apr 20187:17 amEQSHardman & Co Research: Tissue Regenix (TRX): CellRight hits the right note
26th Mar 20187:00 amRNSAnnual results for period ended 31 December 2017
16th Mar 20183:40 pmRNSPublication of Financial Results
8th Mar 20187:15 amRNSHardman & Co: Full-year 2017 - what to look for
6th Mar 20187:00 amRNSLong term distribution agreement with Arthrex, Inc
26th Feb 20187:00 amRNSNotice of Results
26th Feb 20187:00 amRNSLaunch of BioSurgery and new distributor agreement
2nd Feb 20187:00 amRNSIssue of Equity
22nd Dec 20179:30 amRNSIssue of Equity
1st Dec 20177:00 amRNSDirectorate Change
1st Dec 20177:00 amRNSIssue of Equity
2nd Nov 20177:00 amRNSAppointment of CEO
18th Oct 20177:00 amRNSDirectorate Change
11th Oct 20177:15 amRNSHardman Research: Dual revenue stream growth
28th Sep 20173:15 pmRNSUnaudited Interim Results
8th Sep 20177:00 amRNSNotice of Results
5th Sep 20173:52 pmRNSNotification Of Major Holdings
30th Aug 20175:15 pmRNSIssue of Equity
16th Aug 201712:22 pmRNSHolding(s) in Company
11th Aug 20173:45 pmRNSHolding(s) in Company
11th Aug 20173:37 pmRNSHolding(s) in Company
10th Aug 20174:30 pmRNSHolding(s) in Company
10th Aug 20172:45 pmRNSHolding(s) in Company
10th Aug 20171:10 pmRNSHardman Research: CellRight transforming US growth
10th Aug 201710:10 amRNSHolding(s) in Company
9th Aug 20173:00 pmRNSHolding(s) in Company
9th Aug 20172:30 pmRNSDirector/PDMR Shareholding
8th Aug 20171:41 pmRNSResults of General Meeting and Total Voting Rights
21st Jul 20176:00 pmRNSCirc re.CellRight Acquisition
21st Jul 20178:05 amRNSSuccessful fundraising of £40 million
20th Jul 20176:03 pmRNSProposed Acquisition and Placing
30th Jun 201712:00 pmRNSResult of AGM
2nd Jun 20177:00 amRNSAnnual results for period ended 31 December 2016
31st May 201710:46 amRNSPotential Acquisition Update
19th May 201711:35 amRNSPotential Acquisition
3rd Apr 20177:00 amRNSIssue of Equity
13th Mar 20177:10 amRNSHardman Research: Addressing woundcare in the US
1st Mar 20177:00 amRNSInnovative Technology Contract Awarded
2nd Feb 20177:00 amRNSDermaPure® added to the Federal Supply Schedule
6th Jan 20177:00 amRNSDirectorate Change
9th Dec 20167:15 amRNSHardman Research: a/c change: Not simply 11/12ths
7th Dec 20161:04 pmRNSTR1- NOTIFICATION OF MAJOR INTEREST IN SHARES
6th Dec 20167:00 amRNSDermaPure secures GPO agreement with Premier, Inc.
28th Nov 20167:05 amRNSOrthoPureT XT update
22nd Nov 20167:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.